View all newsletters
Receive our newsletter – data, insights and analysis delivered to you


A leading provider of high-quality, system-critical elastomer components, shortlisted in the ENVIRONMENTAL IMPACT category in the 2021 Excellence Awards

Email Address
Gotthardstrasse 31,
More links

The Verdict

Datwyler is shortlisted in our Environmental Impact category in the 2021 Excellence Awards for various initiatives it has taken to reduce its carbon footprint. Principal among these was as a founding member of the Alliance to Zero initiative, which brings together eight companies from across the pharmaceutical supply chain in an effort to comply with a target of net zero emissions by 2030.

The company has already made strides towards this goal transitioning a number of its production plants to renewable electricity including those in Pregnana, Montegaldella, Viadanica, and Karlsbad-Itterbach. With this and other moves the company suggests it has reduced emissions by 12,200 tonnes per year from 2021 and that 40% of its total electricity consumption now comes from renewable energy sources.


Datwyler is focusing on high-quality, system-critical elastomer components and has leading positions in attractive global markets such as healthcare, mobility, and food & beverage.

With its recognized core competencies and technological leadership, the company delivers added value to customers in the markets served. With more than 20 operating companies, sales in over 100 countries and some 7,000 employees, Datwyler generates annual sales of more than CHF 1’000 million.


Within the healthcare solutions business area, Datwyler develops, designs, and manufactures solutions for injectable packaging and drug delivery systems to facilitate customers to create a safer medical environment of tomorrow. Looking back onto more than 100 years of history, Datwyler is a reliable partner, now and in the future!


Gotthardstrasse 31

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology